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estimated the incidence of sarcoidosis to range 
from 3.8 to 4.5/100 000 and reported local dif‑
ferences in incidence rates.8 A large single ‑center 
study from the National Tuberculosis and Lung 
Diseases Research Institute, published in 2018, 
aimed to characterize 1810 patients hospitalized 
from 2010 till 2013.9
In this issue of the Polish Archives of Internal 
Medicine (Pol Arch Intern Med), Bogdan et al10 
reports on sarcoidosis epidemiology in Poland, 
based on data obtained using similar methods. 
Their study provides important information be‑
cause they assessed nationwide data based on 
23 097 patients hospitalized with the diagnosis 
of sarcoidosis from 2008 to 2015. The authors 
estimated the annual incidence rate of sarcoid‑
osis to be 7.5/100000. The 95% confidence inter‑
val was narrow (7.1–7.9), reflecting the study de‑
sign. The prevalence for the end of the studied pe‑
riod of time (2015) was estimated at 60/100 000. 
It should be noted that this estimation concerns 
the whole country population, so the prevalence 
rates in the most commonly affected age groups 
could be about twice as high. Estimations based 
on hospital discharge records are probably slightly 
underrated, because some patients with sarcoid‑
osis might not have been hospitalized for some 
reasons (eg, lack of consent to a hospitalization 
or an invasive diagnostic procedure). However, 
knowing the Polish healthcare settings, the num‑
ber of such patients is most probably small.
The incidence rate reported by Bogdan et al10 is 
higher than that reported by previous local stud‑
ies.8,11 However, this reflects regional differenc‑
es rather than the increasing disease incidence, 
because Bogdan et al10 did not observe a signifi‑
cant increase in the number of hospitalizations 
due to sarcoidosis throughout the study period 
(2008–2015). A higher proportion of men (54.7%) 
is consistent with some recent findings from Po‑
land and other countries,9,12 which is in contrast 
to a widespread opinion that sarcoidosis is more 
common among women.2 The mean age of hos‑
pitalized patients was about 45 years; howev‑
er, this measure is not informative because of 
Sarcoidosis is a multiorgan inflammatory disease, 
characterized by granuloma formation in the af‑
fected organs.1 The disease most commonly in‑
volves the respiratory system, although various 
other sites are often affected.2 Sarcoidosis usual‑
ly remits spontaneously; however, in some cas‑
es, it leads to significant pulmonary fibrosis and 
impairment of lung function, or it can be life‑
‑threatening due to central nervous system or 
cardiac involvement.3 Despite extensive studies, 
the etiology of sarcoidosis remains unknown. 
The genetic and environmental traits have been 
reported, and the most common hypothesis sug‑
gests that an environmental trigger (possibly my‑
cobacteria, propionibacteria, or other organic and 
inorganic substances) provokes a specific response 
in susceptible individuals.2 However, there is no 
firm evidence to support this concept.
There are considerable differences in report‑
ed data on the prevalence of sarcoidosis, with 
the rates ranging from less than 4/100 000 to 
more than 140/100 000.4 Moreover, the preva‑
lence varies across countries and races. In general, 
papers from the United States and Scandinavian 
countries report higher prevalence and suggest 
that sarcoidosis is much more common among in‑
dividuals of African ‑American origin. Also pub‑
lications from Europe differ in reported preva‑
lence, with estimations ranging from 5.9/100 000 
in Greece to more than 150/100 000 in Sweden.5,6 
There is a need for actual data because the prev‑
alence of sarcoidosis has been shown to be ris‑
ing.7 Most reviews report female predominance, 
while recent epidemiological data have suggest‑
ed the opposite.
In healthcare settings where most patients with 
suspected sarcoidosis are hospitalized for diagno‑
sis, hospital ‑based registry data can be used to 
study the epidemiology of sarcoidosis. This also 
holds true for the Polish healthcare system, and 
this methodology can provide valid estimations 
on disease incidence and prevalence. Indeed, some 
recent studies on the epidemiology of sarcoidosis 
in Poland have been performed using this meth‑
od. A study conducted in the Silesian Voivodeship 
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significant sex differences. The peak incidence was 
observed among individuals aged 30 to 39 years 
for men and 50 to 59 years for women, a pattern 
that has been reported in some, but not all, coun‑
tries.2 Similar data on sex ‑age distribution were 
delivered by a recent multicenter European study, 
which included also sites from Poland.13
Data on the affected systems or organs re‑
ported by Bogdan et al10 should be interpreted 
with consideration of the limitations inherent to 
the methods used. There are a couple of caveats 
related to the use of International Classification of 
Diseases, Tenth Revision (ICD ‑10) codes for sarcoid‑
osis. Firstly, the classification provides only one 
common code for sarcoidosis with lymph node in‑
volvement (D86.1). It is safe to assume that most 
patients coded as D86.1 were those with medias‑
tinal lymph node involvement; however, this ap‑
proach excludes cases of sarcoidosis with extra‑
pulmonary lymph node involvement. Second‑
ly, there is only one common code for extrapul‑
monary sarcoidosis (D86.8), and this rules out 
a detailed analysis of extrapulmonary sarcoidosis 
(except for the possibility of using an additional 
code for eye involvement [H22.1], not reported 
by Bogdan et al).10 Overall, the proportions of re‑
spiratory system involvement are within the ex‑
pected range and are similar to those reported by 
another large single ‑center study from Poland.9
In the study by Bogdan et al,10 the propor‑
tion of sarcoidosis with skin involvement was 
only 1.4%, which is much lower than the rates 
reported in other studies.2,13 This may suggest 
that some forms of extrapulmonary sarcoidosis 
might be underdiagnosed in the Polish popula‑
tion. Indeed, we rarely see patients with skin or 
ocular involvement in our everyday practice, de‑
spite the fact that skin and eye involvement is re‑
ported in about 15% and 10% to 30% of patients, 
respectively.2 This is also reflected in some other 
previous Polish reports.9 Apart from underdiag‑
nosis, this discrepancy might have been caused by 
regional differences in sarcoidosis presentation or 
bias related to the use of ICD ‑10 codes (patients 
with lung and extrapulmonary site involvement 
should be theoretically assigned 2 codes, which 
is most probably rarely done).
The paper by Bogdan et al10 provides an im‑
portant insight into the current epidemiology 
of sarcoidosis in Poland. Furthermore, the data‑
base used by the authors offers some possibilities 
for further analyses, for example, of geographi‑
cal differences within Poland. Geographical vari‑
ations within countries have been reported in 
Europe,14,15 and such an analysis could combine 
the available data on residence, environmental 
factors, and clinical presentation, possibly lead‑
ing to some interesting observations.
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